<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:chebi fb="1" ids="50211">Retinol</z:chebi>-binding protein 4 (RBP4) has been identified as a novel adipokine mediating systemic <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, and elevated serum RBP4 indicates overt or impending <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> in lean, <z:mp ids='MP_0001261'>obese</z:mp>, and type 2 diabetic subjects </plain></SENT>
<SENT sid="1" pm="."><plain>As <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> is present in nearly <z:hpo ids='HP_0000001'>all</z:hpo> patients with liver <z:hpo ids='HP_0001394'>cirrhosis</z:hpo>, we evaluated RBP4 in patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver disease</z:e> (CLD) </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: Serum RBP4 was measured in 111 CLD patients </plain></SENT>
<SENT sid="3" pm="."><plain>Ninety-nine age- and sex-matched healthy blood donors served as control subjects </plain></SENT>
<SENT sid="4" pm="."><plain>RBP4 gene expression was also quantified in <z:mpath ids='MPATH_458'>normal</z:mpath> and cirrhotic rat liver </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: In CLD patients, serum RBP4 was significantly reduced compared with healthy control subjects and closely correlated with the stage of liver <z:hpo ids='HP_0001394'>cirrhosis</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>CLD patients without <z:hpo ids='HP_0001394'>cirrhosis</z:hpo> showed <z:mpath ids='MPATH_458'>normal</z:mpath> RBP4 concentrations, which correlated with serum <z:chebi fb="105" ids="17234">glucose</z:chebi> and insulin secretion and inversely correlated with insulin sensitivity </plain></SENT>
<SENT sid="7" pm="."><plain>In patients with Child A-C liver <z:hpo ids='HP_0001394'>cirrhosis</z:hpo>, however, RBP4 was not correlated with <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism or other adipokines, such as adiponectin or resistin, but closely linked to the hepatic biosynthetic capacity, fibrotic changes in liver histology, or clinical complications such as <z:hpo ids='HP_0001409'>portal hypertension</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>In an animal model of experimental <z:hpo ids='HP_0001394'>cirrhosis</z:hpo>, hepatic RBP4 gene expression decreased in cirrhotic liver </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: RBP4 appears, unlike in <z:hpo ids='HP_0001513'>obesity</z:hpo> or type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, not to be a relevant systemic factor in the pathogenesis of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> in liver <z:hpo ids='HP_0001394'>cirrhosis</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>Liver function has a tremendous impact on RBP4 levels, and future studies will need to take liver function into account when examining serum RBP4 levels </plain></SENT>
</text></document>